Severe insulin resistance treated with insulin lispro

Henrichs, H. R.; Unger, H; Trautmann, Michael E.; Pfützner, Andreas

doi:10.1016/s0140-6736(05)65529-8

Cited by 24 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies represent all of the large clinical trials in patients with type 1 diabetic patients using insulin lispro that have been performed to date. None of these studies were powered to detect a significant difference in severe hypoglycemia using the strict criteria of the present study We excluded acute pharmacokinetic trials (17)(18)(19)(20)(21)(22)(23)(24)(25)(26), case reports (27)(28)(29), and smaller studies with different objectives or the lack of a control group treated with human soluble insulin (30-33). The total of 233 patients from these small studies was not included in this meta-analysis.…”

Section: Research Design Andmentioning

confidence: 99%

Meta-Analysis of the Effect of Insulin Lispro on Severe Hypoglycemia in Patients With Type 1 Diabetes

Llewelyn²,

Jh³

et al. 1998

Diabetes Care

183

View full text Add to dashboard Cite

show abstract

Section: Research Design Andmentioning

confidence: 99%

Meta-Analysis of the Effect of Insulin Lispro on Severe Hypoglycemia in Patients With Type 1 Diabetes

Llewelyn²,

Jh³

et al. 1998

Diabetes Care

183

View full text Add to dashboard Cite

show abstract

“…nsulin antibodies have been linked with cutaneous and systemic allergic reactions (1-11) and insulin resistance (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Before highly purified insulin products, allergic responses were seen in up to 30% of patients.…”

mentioning

confidence: 99%

Effect of Long-Term Exposure to Insulin Lispro on the Induction of Antibody Response in Patients With Type 1 or Type 2 Diabetes

et al. 2003

View full text Add to dashboard Cite

OBJECTIVE -To determine the long-term effects of insulin lispro on inducing lisprospecific, insulin-specific, and cross-reactive (reactive with both insulin lispro and human insulin) antibodies. RESEARCH DESIGN AND METHODS-A multinational, multicenter combination of controlled and noncontrolled, open-label studies of 4.5 years' duration was designed to evaluate the long-term immunologic profile of subcutaneously administered insulin lispro. A total of 1,221 patients (men and women; 12-81 years of age) with type 1 or type 2 diabetes were enrolled. Circulating anti-insulin antibodies were measured using radioimmunoassays.RESULTS -Insulin-specific and lispro-specific antibody responses were within the background noise levels of the assays. Significant elevations of antibody were confined to a crossreactive antibody response. Antibody levels resulting from prior exposure to long-and shortacting insulins changed little after transfer to insulin lispro and remained within or near the baseline levels. De novo exposure to insulin lispro resulted in increases in cross-reactive but not insulin-or lispro-specific antibody levels. Cross-reactive insulin antibodies developed more readily in patients with type 1 diabetes than in those with type 2 diabetes. Long-term antibody responses tended to decrease over time and returned to baseline or near-baseline levels by the end of the long-term studies. No evidence of an anamnestic antibody response could be found in individuals treated intermittently with insulin lispro.CONCLUSIONS -The immunogenic profile of patients treated with insulin lispro was comparable to that of patients treated with recombinant human insulin. Inductions of significant levels of specific or cross-reactive antibodies were not observed in patients who had received insulin previously. No significant antibody-dependent increases in insulin dosage requirements were noted in these patients. The incidence of insulin allergy was not different from that in patients treated with recombinant regular human insulin. Diabetes Care 26:89 -96, 2003

show abstract

“…Antibodies specifi c against insulin lispro hardly ever develop and do not aff ect dose requirements [80,83]. Interestingly, there have been reports of patients in whom severe resistance to human insulin due to antibody formation was successfully overcome by switching them to insulin lispro [84,85].…”

Section: Scientifi C Informationmentioning

confidence: 99%

Review of insulin and its analogues in diabetes mellitus

Mane¹,

Chaluvaraju²,

Niranjan³

et al. 2012

J Basic Clin Pharma

View full text Add to dashboard Cite

DIABETES MELLITUSD iabetes mellitus (DM) is a metabolic disorder resulting from a defect in insulin secretion, insulin action or both [1][2][3][4]. Insulin defi ciency in turn leads to chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism [1][2][3][4]. As the disease progresses tissue or vascular damage ensues leading to severe diabetic complications such as retinopathy [5,6], neuropathy [7,8], nephropathy [9,10], Cardiovascular complications [11,12] and ulceration [13,14]. Th us diabetes covers a wide range of heterogeneous diseases. Diabetes is the most common endocrine disorder and by the year 2010, it was estimated that more than 200 million people worldwide had DM and 300 million will subsequently have the disease by 2025 [15][16][17]. Th e diagnostic criteria and the classifi cation of diabetes was fi rst put forward by the World Health Organization (WHO) in 1965[18] then by the National Diabetes Data Group (NDDG) in 1979 [19] and this was followed by simplifi ed recommendations by the WHO in 1980 [20]. Th ese WHO recommendations were modifi ed slightly in 1985 [21]. Th e latest recommendations have been published by the American Diabetes Association (ADA) in 1997 and by the WHO in 1999. Both groups agree on the recommendations and criteria [2,22].According to the ADA recommendation changes in 1997, the fasting glucose concentration should be used in routine screening for diabetes as well as epidemiological studies; the threshold for fasting glucose was changed from 7.8 mmol/L (140 mg/dl) to 7.0 mmol/L (126 mg/dl); however the 2 hrs glucose criterion remains as 11.1 mmol/L (200 mg/dL). For the diagnosis of diabetes, at least one of the below criteria must apply. Th e WHO diagnosis and classifi cation of diabetes mellitus (1999) are identical to those of ADA, a fasting glucose = 7.0 mmol/L (126 mg/dl) and /or a 2 hrs glucose = 11.1 mmol/L (200 mg/dL). Th e report states that diagnosis should not be based on a single glucose determination but requires confi rmatory symptoms or blood/plasma determination. Ideally therefore, both the 2 hrs and fasting value should be used. Th ese recommendations contrast with those of ADA Expert Committee which gives primacy to the fasting plasma glucose. Th e WHO classifi cation includes both clinical stages (normoglycaemia, impaired glucose tolerance/impaired fasting glucose (IGT/IFG), diabetes and aetiological types of diabetes mellitus, identical to the ADA except that WHO group includes classifi cation formerly known as gestational impaired glucose tolerance (GIGT) and GDM: fasting glucose = 7.0 mmol/L (126 mg/dL) and/or 2 hrs glucose = 7.8 mmol/ L (140 mg/dL) after a 75-g OGTT.Diabetes mellitus may be categorized into several types but the two major types are type I and type II [21,23]. On the basis of aetiology, the term type I and type II were widely used to describe IDDM and NID-DM, respectively. Th e term juvenile -onset diabetes has sometimes been used for IDDM and maturity-onset for NIDDM.Type I (Ia, Ib) ß-cell destruction with litt...

show abstract

Severe insulin resistance treated with insulin lispro

Cited by 24 publications

References 2 publications

Meta-Analysis of the Effect of Insulin Lispro on Severe Hypoglycemia in Patients With Type 1 Diabetes

Meta-Analysis of the Effect of Insulin Lispro on Severe Hypoglycemia in Patients With Type 1 Diabetes

Effect of Long-Term Exposure to Insulin Lispro on the Induction of Antibody Response in Patients With Type 1 or Type 2 Diabetes

Review of insulin and its analogues in diabetes mellitus

Contact Info

Product

Resources

About